2025-12-31 - Analysis Report
Okay, let's break down the provided data for Merck & Co. (MRK).

**1) Return Rate Comparison**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of healthcare products.
*   **MRK Cumulative Return:** 26.16%
*   **VOO (S&P 500) Cumulative Return:** 102.21%
*   **Divergence:** -76.2 (Relative Divergence: 21.9)

**Analysis:** MRK has significantly underperformed the S&P 500 over the period examined.  The divergence of -76.2% indicates a substantial difference in returns. The relative divergence of 21.9 suggests the current divergence is near the low end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B)  |
|------------|--------|--------|--------|-------|---------|
| 2015-2017  | 1.0%   | 68.5%  | -28.0% | 0.0   | 134.1   |
| 2016-2018  | 36.0%  | 69.8%  | 21.0%  | -0.0  | 182.1   |
| 2017-2019  | 40.0%  | 69.8%  | 18.0%  | 0.3   | 216.8   |
| 2018-2020  | 16.0%  | 79.6%  | -8.0%  | 0.3   | 195.0   |
| 2019-2021  | 2.0%   | 79.6%  | -44.0% | 0.7   | 191.4   |
| 2020-2022  | 15.0%  | 79.6%  | 16.0%  | 0.7   | 277.1   |
| 2021-2023  | 33.0%  | 79.6%  | 31.0%  | 0.3   | 272.3   |
| 2022-2024  | -4.0%  | 79.6%  | -25.0% | 0.2   | 248.5   |
| 2023-2025  | -23.0% | 71.5%  | -90.0% | 1.8   | 264.9   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Fluctuates significantly, with recent periods (2022-2025) showing negative growth.
*   **MDD (Maximum Drawdown):** Consistently high, indicating periods of significant price decline.
*   **Alpha:** Shows mixed performance.  Negative alpha suggests underperformance relative to its benchmark, while positive alpha indicates outperformance.  The recent period (2023-2025) has a very large negative alpha, indicating significant underperformance.
*   **Beta:** Generally low, suggesting MRK is less volatile than the market. However, the recent increase to 1.8 suggests a higher correlation and volatility relative to the market.
*   **Cap(B) Market Capitalization:** Indicates an increase in market cap throughout the provided period.

**2) Recent Stock Price Fluctuations**

*   **Close:** 106.06
*   **Previous Close:** 106.62
*   **Change:** -0.53
*   **5-day SMA:** 106.19
*   **20-day SMA:** 101.633
*   **60-day SMA:** 93.88

**Analysis:** The stock price closed slightly lower than the previous day. The 5-day SMA is slightly above the current price, while the 20-day and 60-day SMAs are significantly lower. This suggests a recent upward trend, as the short-term moving averages are higher than the longer-term averages, though the last market movement was down.

**3) RSI, PPO, and Market Risk Indicators**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 81.25 (Overbought)
*   **PPO (Percentage Price Oscillator):** 0.254
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (2 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** 2.4 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -39.6%

**Analysis:**

*   The high RSI indicates the stock is overbought and may be due for a correction.
*   The PPO suggests some positive momentum, but it's relatively low.
*   The Market Risk Indicator suggests a High Investment Recommendation, which seems at odds with the overbought RSI.
*   The Hybrid Signal suggests a strong buy recommendation, which is contrary to some of the other indicators.
*   The recent relative divergence change suggests a short-term increase.
*   The **Expected Return of -39.6% is a major red flag, suggesting significant downside potential over the long term.** This is very concerning.

**4) Recent News & Significant Events**

*   **Positive Headlines:** Some headlines suggest MRK is a good value stock for the long term and analyze its potential. Some headlines discuss the company's valuation compared to peers.
*   **Negative/Cautious Headlines:** One headline notes Farmers & Merchants Investments Inc. Cuts Stock Position in Merck & Co., Inc.. One headline discusses a potential slowdown post-2028.

**Analysis:** The news is mixed. While some articles highlight the value proposition of MRK, others point to potential headwinds and institutional selling. The analysis needs to consider both positive and negative perspectives.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.90)
*   **Target Price:** Average: 110.04, High: 139.00, Low: 83.00
*   **Recent Rating Changes:** Not provided.

**Analysis:** Analysts generally have a "Buy" rating on MRK, and the average target price is slightly above the current price. However, there is a wide range in target prices, indicating some uncertainty. The lack of recent rating changes makes it difficult to assess the latest sentiment.

**5) Recent Earnings Analysis**

| 날짜        | EPS  | 매출       |
|-------------|------|------------|
| 2025-11-05 | 2.32 | 17.28 B$   |
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2025-11-05 | 1.25 | 16.66 B$   |

**Analysis:**

*   EPS (Earnings Per Share) has fluctuated, with the most recent quarter showing the highest EPS.
*   Revenue has also fluctuated, with the most recent quarter showing the highest revenue.
*   The repetition of the 2024-11-06 EPS and revenue for 2025-11-05 is unusual and may indicate a data error and needs verification.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30  | $17.28B   | 77.69%        |
| 2025-06-30  | $15.81B   | 77.50%        |
| 2025-03-31  | $15.53B   | 77.98%        |
| 2024-12-31  | $15.62B   | 75.50%        |
| 2024-09-30  | $16.66B   | 75.51%        |

**Analysis:**

*   Revenue has shown a general upward trend.
*   Profit margins are very high and relatively stable, indicating strong profitability.

**Capital and Profitability:**

| Quarter      | Equity      | ROE    |
|--------------|-------------|--------|
| 2025-09-30  | $51.85B    | 11.16% |
| 2025-06-30  | $48.99B    | 9.04%  |
| 2025-03-31  | $48.34B    | 10.51% |
| 2024-12-31  | $46.31B    | 8.08%  |
| 2024-09-30  | $44.50B    | 7.09%  |

**Analysis:**

*   Equity has steadily increased, showing growth in the company's net assets.
*   ROE (Return on Equity) has fluctuated but is generally increasing, indicating improved profitability relative to equity.

**7) Comprehensive Analysis (Summary)**

Overall, the analysis paints a mixed picture of Merck & Co. (MRK).

*   **Negative Signals:** MRK has significantly underperformed the S&P 500. The very negative expected return (-39.6%) is a major concern. The stock appears to be overbought (high RSI). The large negative Alpha for recent periods shows significant underperformance. One recent news article reports that Farmers & Merchants Investments Inc. Cuts Stock Position in Merck & Co., Inc.
*   **Positive Signals:** Recent revenue and profit margins are strong. Equity and ROE are generally increasing. Analysts have a "Buy" consensus and the Market Risk Indicator suggests a High Investment Recommendation. Some news headlines suggest the stock is undervalued.
*   **Mixed Signals:** Beta has recently increased, suggesting higher volatility. The Hybrid Signal conflicts with other indicators.

**Conclusion:**

While MRK has strong financial performance in terms of revenue, profit margins, equity, and ROE, the significantly negative expected return and underperformance compared to the S&P 500 are major concerns. The overbought RSI suggests a potential pullback.

**Recommendation:**

A cautious approach is warranted. The negative expected return and underperformance raise serious questions about the stock's future prospects. Further investigation is needed to understand the reasons behind the negative expected return and to assess the potential impact of a possible slowdown post-2028, as mentioned in one of the news headlines. It's important to reconcile the conflicting signals from the Market Risk Indicator and Hybrid Signal with the other negative indicators.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.